StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Monday. The firm issued a hold rating on the stock.

EKSO has been the topic of a number of other reports. HC Wainwright reduced their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Stock Performance

EKSO opened at $0.77 on Monday. The firm has a market capitalization of $17.03 million, a PE ratio of -1.19 and a beta of 1.47. Ekso Bionics has a twelve month low of $0.77 and a twelve month high of $3.13. The firm’s 50-day moving average price is $1.07 and its 200 day moving average price is $1.12. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same period last year, the firm earned ($0.24) earnings per share. As a group, sell-side analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.